PLANNING, DESIGN & ACCESS STATEMENT PCI Pharma Services Unit 23-24 Tafarnaubach Industrial Estate March 2020 T: 029 2073 2652 T: 01792 480535 Cardiff Swansea E: [email protected] W: www.asbriplanning.co.uk PROJECT SUMMARY PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE Description of development: Construction of new packaging line building, retaining wall and covered pedestrian walkway linking new packaging line building with new car park (approved under Application Ref C/2019/0195) Location: Unit 23-24 Tafarnaubach Industrial Estate, Tredegar Date: March 2020 Asbri Project ref: 20.159 Client: PCI Pharma Services STATEMENT A C CE S S & PLANNING, DESIGN Asbri Planning Ltd Prepared by Approved by Unit 9 Oak Tree Court Mulberry Drive Geraint Jones Pete Sulley Cardiff Gate Business Park Name Cardiff Planner Director CF23 8RS T: 029 2073 2652 Date March 2020 March 2020 E: [email protected] W: asbriplanning.co.uk Revision M AR C H 2 0 2 0 2 CONTENTS PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE Section 1 Introduction 5 Section 2 Site Context and Analysis 6 Section 3 Interpretation 8 Section 4 Design Development 10 Section 5 Planning Policy 12 STATEMENT Section 6 The Proposal 15 Section 7 A C CE S S Appraisal 19 & Section 8 Conclusion 21 PLANNING, DESIGN M AR C H 2 0 2 0 3 PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE SITE IN REGIONAL CONTEXT STATEMENT A C CE S S & PLANNING, DESIGN M AR C H 2 0 2 0 4 PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE INTRODUCTION 1.1 This Planning, Design and Access Statement (PDAS) has 1.5 The submitted Planning, Design and Access Statement 1.11 PCI Tredegar has begun an expansion of its facility to been prepared on behalf of PCI Pharma Services to accompany adheres to guidance embodied in the Welsh Government enhance its high potent drug manufacturing and development a full planning application for the construction of new publication, Design and Access Statements in Wales, capabilities, including both clinical and commercial supply packaging line building, retaining wall and covered pedestrian published in June 2017. which will support with the growth of the business. At present walkway linking new packaging line building with new car park PCI Tredegar employs over 440 members of staff (the largest (approved under Application Ref C/2019/0195) at Unit 23-24 Background, Vision and Brief employer in Blaenau Gwent) which will increase significantly Tafarnaubach Industrial Estate, Tredegar, Blaenau Gwent. 1.6 As a respected industry leader and trusted partner, PCI over the next 5 years with the forecasted business growth; the provide a comprehensive range of pharmaceutical services already approved CMF2 building and this Packaging Line 1.2 The purpose of a Planning, Design & Access Statement from the earliest stages of development through to Building are the first phases of this growth programme. (DAS) is to provide a clear and logical document to commercial launch and ongoing supply. demonstrate and explain the various facets of design and 1.12 The vision for the proposed development is to deliver a access in relation to the site and to appraise the proposed 1.7 PCI combine best-in-class technologies with cutting- packaging line building which will result in a series of development against relevant planning policies. It also edge research supported by an exceptional team of people, economic benefits not only for the operator but also in the presents the details of a planning application in a way that can delivering the highest level of regulatory compliance and form of significant job creation. It is considered that the STATEMENT be read both by professionals and the public. quality standards. Equally important is our commitment to majority of positions will be occupied by local persons, as such, providing an industry-leading customer experience, sharing the scheme will contribute to the economic development of 1.3 The diagram right, extracted from Planning Policy Wales, our customers’ passion for supplying often lifesaving Blaenau Gwent County Borough. summarises the five objectives of good design that should be medicines to patients around the world. PCI are committed A C CE S S taken into account when preparing a DAS. The circular nature to meeting the evolving needs of our clients by leveraging 1.13 The brief for the development was to develop a packaging & of the diagram represents the equal weightings that need to our experience and expertise to always deliver the best line building which integrated seamlessly into the wider PCI be given to each of the 5 Objectives of Good Design: Access; possible solution operation. Further, the scheme is required to be linked to the Movement; Character; Environmental Sustainability and CMF2 building and car park approved under application Community Safety. 1.8 PCI Tredegar provides full development and C/2019/0195. manufacturing services for both investigational and 1.4 Accordingly, the statement is subdivided into seven commercial products including highly potent molecules sections, commencing with this introductory chapter in this requiring specialist handling. section which includes the brief and vision. Section 2 provides a brief overview of the site context and its surroundings. 1.9 With over 35 years’ experience of processing potent and Section 3 interprets and applies the context of the brief and non-potent drug products, PCI provides a true partnership PLANNING, DESIGN vision for the site, whilst section 4 summarises how the design and consultative approach from pre-clinical formulation has developed from the initial stages. Section 5 provides the development and API characterization through to full relevant national and local planning policy context, followed commercial launch. by Section 6 which sets out the proposal and explores the relevant design and access facets associated with the 1.10 When it comes to caring for humanity, ensuring life- application whilst Section 7 appraises the development against changing medicines reach those who need it most is our relevant policies. The document then concludes under Section highest priority. As manufacturing and supply chain experts, 8 which summarises the key themes running through the PCI use our experience and expertise to navigate every report, justifying that the proposed development should be challenge PCI may face on behalf of our clients with the granted planning permission. ultimate aim of improving the lives of patients. M AR C H 2 0 2 0 5 PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE SITE IN LOCAL CONTEXT STATEMENT A C CE S S SITE LOCATION PLAN & PLANNING, DESIGN M AR C H 2 0 2 0 6 PCI PHARMA SERVICES, TAFARNAUBACH INDUSTRIAL ESTATE SUMMARY OF THE PROPOSAL Site Context construction, lies the Eastern Ridge and Mynydd James Reference: C/2019/0195 2.1 The site is located immediately north of the existing PCI Special Landscape Area. The site is positioned outside of the Description: A new pharmaceutical containment facility and Pharma Services facility, but still within its curtilage, and SLA and within an industrial estate, as such, will not impact ancillary infrastructure (e.g. chillers), extended service yard and centred on the following grid coordinates: E: 312490, N: upon the character of the area. new car park including associated engineering/land upgrading 210929. works. It is proposed that the car park is built at the top of the 2.7 Tafarnaubach Industrial Estate is strategically located site on previously unused land. 2.2 The PCI facility lies within Tafarnaubach Industrial Estate, immediately north of the A465 Heads of the Valleys Road, as Decision: Granted on 2nd October 2019 Tredegar, and is positioned north of the main town beyond such, the site is accessible via major highway infrastructure. the A465, Heads of the Valleys Road towards the Brecon Reference: C/2020/0033 Beacons. 2.8 In relation to public transport, the closest bus stop to the Description: Three storey lab block, external stairs, associated site is located along Merthyr Road approximately 50 metres canopies Site Features to the south of the A465 overbridge and around 1km (12 Decision: Granted on 12th March 2020 2.3 The site where the building is to be positioned is largely minute walk or a 3 minute cycle) from the proposed rectangular in shape and measures approximately 850m². It development site. One service operates from the stop and STATEMENT currently comprises 44no. of car parking spaces on a provides users with transport to Tredegar Town and tarmacadam surface. Vehicular access to the site is achieved Rhymney. via the main access to the wider PCI Pharma Services facility to the south. 2.9 A review of Wales’ Historic Environment Record reveals A C CE S S that there are no historical assets immediately adjacent to & 2.4 It is positioned immediately adjacent to a recently the site. Indeed, the nearest relates to Blaen y Cwm Viaduct, consented pharmaceutical containment facility approved which is afforded Grade II Listed Status (CADW Ref: 1860) under planning permission C/2019/0195 and south of a situated approximately 800m east of the application site. The large car park comprising approximately 180no. spaces site is screened from the structure by varying topography, approved under the same application. and residential development, as such, its development will not impact the setting of the historical asset. 2.5 A review of Natural Resources Wales’ Development Advice Map reveals that the site lies within Flood Zone A, as Planning History such, is considered to be at little or no risk of fluvial or tidal/ 2.10 The following applications relating to the site itself and coastal flooding. wider PCI Facility are considered relevant to this application: PLANNING, DESIGN Surroundings Reference: C/2011/0167 2.6 The site’s immediate surroundings comprise the wider Description: Revised staff car park and vehicle access and PCI facility which has been subject to a number of construction of new manufacturing building.